A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to Standard of Care in Virologically Suppressed Adults Living with HIV

14800209639-VH3810109OpenA Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to Standard of Care in Virologically Suppressed Adults Living with HIVNCT05291520IndustrialAdultTreatmentIIOtherKumar, PrincyGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Medicine Infectious Disease; GUMC PFS2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>